Tandem Diabetes Care (TNDM) Cash from Investing Activities (2013 - 2026)
Tandem Diabetes Care's (TNDM) quarterly Cash from Investing Activities came in at -$195.4 million in Q1 2026, down 2227.67% YoY from $9.2 million in Q1 2025, and down 1205.07% on a QoQ basis from -$15.0 million in Q4 2025.
Tandem Diabetes Care (TNDM) Cash from Investing Activities (2013 - 2026) Analysis & Trends
Tandem Diabetes Care (TNDM) has 14 years of Cash from Investing Activities data on file, last reported at -$195.4 million in Q1 2026.
- Quarterly Cash from Investing Activities fell 2227.67% year-over-year to -$195.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$131.8 million (down 1325.95% YoY) and the FY2025 annual result came in at $72.9 million, up 410.35% from the prior year.
- Cash from Investing Activities eased to -$195.4 million in Q1 2026, from -$15.0 million in the prior quarter.
- In the past five years, Cash from Investing Activities ranged from a high of $58.1 million in Q2 2025 to a low of -$195.4 million in Q1 2026.
- A 5-year average of -$11.7 million and a median of -$3.5 million in 2024 frame the typical range for Cash from Investing Activities.
- Annual changes were most pronounced in 2025 — Cash from Investing Activities surged 1742.09% — and 2026, when it tumbled 2227.67%.
- Tracing TNDM's Cash from Investing Activities over 5 years: stood at $35.8 million in 2022, then slumped by 146.35% to -$16.6 million in 2023, then surged by 130.21% to $5.0 million in 2024, then tumbled by 398.92% to -$15.0 million in 2025, then sank by 1205.07% to -$195.4 million in 2026.
- The last three Cash from Investing Activities figures came in at -$195.4 million (Q1 2026), -$15.0 million (Q4 2025), and $20.5 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 202.72 Bn | 197.12 Bn | 7.27 Bn | -673.00 Mn |
| 2 | Stryker | 126.42 Bn | 122.94 Bn | 4.50 Bn | -639.00 Mn |
| 3 | Medtronic | 119.75 Bn | 110.53 Bn | 6.41 Bn | -917.00 Mn |
| 4 | Boston Scientific | 74.13 Bn | 73.60 Bn | 3.85 Bn | -1.96 Bn |
| 5 | Edwards Lifesciences | 51.78 Bn | 47.53 Bn | 1.35 Bn | -193.20 Mn |
| 6 | Dexcom | 35.29 Bn | 33.34 Bn | 830.00 Mn | 329.80 Mn |
| 7 | GE HealthCare Technologies | 33.95 Bn | 31.85 Bn | 2.18 Bn | -115.00 Mn |
| 8 | Koninklijke Philips | 26.22 Bn | 22.90 Bn | 4.55 Bn | -22.08 Mn |
| 9 | Steris | 23.21 Bn | 22.73 Bn | 684.20 Mn | -108.50 Mn |
| 10 | Tandem Diabetes Care | 1.56 Bn | 1.10 Bn | 144.78 Mn | -87.34 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -87.34 Mn |
| Jun 30, 2026 | -87.34 Mn |
| Mar 31, 2026 | -195.45 Mn |
| Mar 31, 2026 | -195.45 Mn |
| Dec 31, 2025 | -14.98 Mn |
| Dec 31, 2025 | -14.98 Mn |
| Sep 30, 2025 | 20.54 Mn |
| Sep 30, 2025 | 20.54 Mn |
| Jun 30, 2025 | 58.13 Mn |
| Jun 30, 2025 | 58.13 Mn |
| Mar 31, 2025 | 9.19 Mn |
| Mar 31, 2025 | 9.19 Mn |
| Dec 31, 2024 | 5.01 Mn |
| Dec 31, 2024 | 5.01 Mn |
| Sep 30, 2024 | -19.90 Mn |
| Sep 30, 2024 | -19.90 Mn |
| Jun 30, 2024 | -3.54 Mn |
| Jun 30, 2024 | -3.54 Mn |
| Mar 31, 2024 | -5.06 Mn |
| Mar 31, 2024 | -5.06 Mn |